Y
Yafeng Xue
Researcher at AstraZeneca
Publications - 60
Citations - 2804
Yafeng Xue is an academic researcher from AstraZeneca. The author has contributed to research in topics: Active site & Carbonic anhydrase. The author has an hindex of 30, co-authored 59 publications receiving 2602 citations. Previous affiliations of Yafeng Xue include Griffith University & Umeå University.
Papers
More filters
Journal ArticleDOI
Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418
Ratan Bhat,Yafeng Xue,Stefan von Berg,Sven Hellberg,Mats Ormö,Yvonne Nilsson,Ann-Cathrin Radesäter,Eva Jerning,Per-Olof Markgren,Thomas Borgegård,Martin Nylöf,Alfredo Giménez-Cassina,Félix Hernández,José J. Lucas,Javier Díaz-Nido,Jesús Avila +15 more
TL;DR: AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5 and may have important applications as a tool to elucidate the role of Gsk3 in cellular signaling and possibly in Alzheimer's disease.
Journal ArticleDOI
Exploitation of Structural and Regulatory Diversity in Glutamate Racemases
Tomas Lundqvist,Stewart L. Fisher,Gunther Kern,Rutger H. A. Folmer,Yafeng Xue,D. Trevor Newton,Thomas A. Keating,Richard A. Alm,Boudewijn L. M. de Jonge +8 more
TL;DR: Three distinct mechanisms of regulation for the family of glutamate racemases are described: allosteric activation by metabolic precursors, kinetic regulation through substrate inhibition, and d-glutamate recycling using a d-amino acid transaminase.
Journal ArticleDOI
Inhibition and catalysis of carbonic anhydrase
TL;DR: The zinc enzyme carbonic anhydrase (carbonate hydrolyase) has been intensely investigated since its discovery and the kinetics and inhibition of the enzyme have been extensively studied and repeatedly reviewed.
Journal ArticleDOI
Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines.
Stefan von Berg,Margareta Bergh,Sven Hellberg,Katharina Högdin,Yvonne Lo-Alfredsson,Peter Söderman,Stefan Berg,Tatjana Weigelt,Mats Ormö,Yafeng Xue,Julie A. Tucker,Jan A.M. Neelissen,Eva Jerning,Yvonne Nilsson,Ratan Bhat +14 more
TL;DR: This work has developed highly potent and selective inhibitors of GSK3β showing cellular efficacy and blood-brain barrier penetrance that are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.
Journal ArticleDOI
Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide
Yafeng Xue,Petter Björquist,Tord Inghardt,Marcel Linschoten,Djordje Musil,Lennart Sjölin,Johanna Deinum +6 more
TL;DR: The characterisation of the two binding sites for the peptide inhibitor provides a solid foundation for computer-aided design of novel, low molecular weight PAI-1 inhibitors.